Leichter H E, Salusky I B, Ettenger R B, Jordan S C, Hall T L, Marik J, Fine R N
Am J Kidney Dis. 1986 Sep;8(3):181-5. doi: 10.1016/s0272-6386(86)80022-1.
For children with end-stage renal disease, renal transplantation is the ultimate goal because it offers the potential of maximum rehabilitation. In order to evaluate the infectious risk of renal transplantation in patients previously maintained on continuous ambulatory peritoneal dialysis (CAPD) and/or continuous cycling peritoneal dialysis (CCPD), we retrospectively evalauted the clinical course of 44 pediatric patients (mean age 12.0 +/- 5.7 [SD] years) who received 32 cadaver and 16 live-related donor renal grafts after being maintained on peritoneal dialysis for 756 patient-months (mean 17.1 +/- 11.5 months). In the posttransplant period, 25 patients (57%) required dialysis because of acute tubular necrosis or acute rejection. Peritonitis developed in five patients (11%) following transplantation; two were being dialyzed at the time. Exit-site and tunnel infections occurred in nine patients (20%). In all instances, antibiotic treatment and/or catheter removal was curative. Posttransplant ascites developed in 12 patients (27%) and was alleviated by catheter drainage. The catheters were left in situ at the time of transplantation and electively removed when stable graft function was present. The 1- and 2-year actuarial graft survival rate was 65% and 55%, respectively. One patient died in the immediate posttransplant period, which was unrelated to peritoneal dialysis. In conclusion, pediatric patients maintained on CAPD and/or CCPD can be safely transplanted. The potential infectious risks related to peritoneal dialysis can be managed with appropriate management of the catheter and prompt antibiotic therapy. The patient and graft survival rates are comparable to those with patients receiving hemodialysis prior to transplantation. There is no need to limit access to transplantation in children undergoing CAPD and/or CCPD.
对于终末期肾病患儿而言,肾移植是最终目标,因为它提供了最大程度康复的潜力。为了评估既往接受持续非卧床腹膜透析(CAPD)和/或持续循环腹膜透析(CCPD)的患者进行肾移植的感染风险,我们回顾性评估了44例儿科患者(平均年龄12.0±5.7[标准差]岁)的临床病程,这些患者在接受腹膜透析756个患者月(平均17.1±11.5个月)后接受了32例尸体供肾和16例亲属活体供肾移植。在移植后期间,25例患者(57%)因急性肾小管坏死或急性排斥反应需要透析。移植后有5例患者(11%)发生腹膜炎;其中2例在透析时发生。9例患者(20%)发生出口处和隧道感染。在所有病例中,抗生素治疗和/或拔除导管均治愈。12例患者(27%)出现移植后腹水,通过导管引流得以缓解。移植时导管保留原位,在移植肾功能稳定时择期拔除。1年和2年的移植精算生存率分别为65%和55%。1例患者在移植后即刻死亡,与腹膜透析无关。总之,接受CAPD和/或CCPD的儿科患者可以安全地进行移植。与腹膜透析相关的潜在感染风险可以通过适当管理导管和及时使用抗生素治疗来控制。患者和移植肾的生存率与移植前接受血液透析的患者相当。对于接受CAPD和/或CCPD的儿童,无需限制其获得移植的机会。